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Effects of cortisol administration on craving in heroin addicts
MWalter1, D Bentz1,2,6, N Schicktanz2,6, A Milnik1,3, A Aerni2, C Gerhards2, K Schwegler1,2, M Vogel1, J Blum1, O Schmid1, B Roozendaal4,
UE Lang1, S Borgwardt1 and D de Quervain1,2,5
Heroin dependence is a severe and chronically relapsing substance use disorder with limited treatment options. Stress is known to
increase craving and drug-taking behavior, but it is not known whether the stress hormone cortisol mediates these stress effects or
whether cortisol may rather reduce craving, for example, by interfering with addiction memory. The aim of the present study was to
determine the effects of cortisol administration on craving in heroin-dependent patients and to determine whether the effects
depend on the daily dose of heroin consumption. We used a double-blind, placebo-controlled, cross-over study in 29 heroin-
dependent patients in a stable heroin-assisted treatment setting. A single oral dose of 20mg of cortisol or placebo was
administered 105 min before the daily heroin administration. The primary outcome measure was cortisol-induced change in
craving. Secondary measures included anxiety, anger and withdrawal symptoms. For the visual analog scale for craving, we found a
signiﬁcant interaction (P= 0.0027) between study medication and heroin-dose group (that is, daily low, medium or high dose of
heroin). Cortisol administration reduced craving in patients receiving a low dose of heroin (before heroin administration: P= 0.0019;
after heroin administration: P= 0.0074), but not in patients receiving a medium or high dose of heroin. In a picture-rating task with
drug-related pictures, cortisol administration did not affect the ratings for the picture-characteristic craving in all the three heroin-
dose groups. Cortisol also did not signiﬁcantly affect secondary outcome measures. In conclusion, a single administration of cortisol
leads to reduced craving in low-dose heroin addicts. The present ﬁndings might have important clinical implications with regard to
understanding stress effects and regarding treatment of addiction.
Translational Psychiatry (2015) 5, e610; doi:10.1038/tp.2015.101; published online 28 July 2015
INTRODUCTION
Opioid dependence, most commonly manifested as heroin
dependence, is estimated to affect between 13 and 22 million
persons worldwide.1 The risks of heroin dependence include fatal
overdoses, infections (including endocarditis, human immunode-
ﬁciency virus infection and hepatitis C virus infection), social
disintegration, violence and crime.2 Heroin dependence is
generally known to be a chronically relapsing disorder that is
characterized by compulsive drug use and loss of control over
drug intake.3 The compulsion to use heroin is frequently driven by
craving—a subjective experience of wanting to use and re-
experiencing the positive effect of the drug.4,5 Clinical research
has demonstrated that opioid maintenance programs with regular
opioid administration, including pharmaceutical heroin (diacetyl-
morphine), produce favorable treatment retention and reduce
illicit opioid use in heroin-dependent patients.6 However, a
substantial fraction of patients, especially during methadone
maintenance treatment, continue to experience heroin craving
and show illicit heroin use.7
Acute withdrawal in heroin addiction is accompanied by a
negative affective state characterized by dysphoria, irritability,
anxiety, as well as abnormal stress reactivity that drives drug
seeking through negative reinforcement mechanisms.8,9 For
instance, abstinent heroin-dependent individuals show elevated
stress reactivity, which is related to heightened craving and
symptoms of withdrawal.10 Indeed, an activation of the hypotha-
lamic–pituitary–adrenocortical axis and elevated glucocorticoid
(that is, cortisol in humans) levels have been reported during
opioid withdrawal syndromes,11 while opioid agonists were
associated with a reduction in cortisol secretion.12 Furthermore,
we found suppressed salivary cortisol concentrations,13 reduced
craving scores and amygdala activity after opioid administration in
heroin-dependent patients.14–16 Moreover, the opioid partial
agonist buprenorphine has been found to dampen responses to
psychosocial stress in healthy humans.17
Stress (that is, stressful live events and stressful conditions) has
been found to increase craving and the risk of relapse to opioid
use.18–20 It is not known, however, whether glucocorticoids are
involved in mediating these stress effects. In case they are, the
administration of glucocorticoids in heroin addicts could result in
increased craving. On the other hand, exogenous glucocorticoid
administration has been shown to induce temporary reduction in
the retrieval of different forms of memory, including aversive
memory in anxiety disorders,21 and could therefore also reduce
addiction-related memory. The neurobiology of drug addiction
shares striking commonalities with the neurobiology of learning
and memory, including shared neural circuitries and molecular
mechanisms.22,23 In line with these neurobiological models of
addiction memory, studies in addicted patients have indicated
that the evocation of conditioned responses by drug-associated
stimuli is important in the maintenance of drug use and
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relapse.24,25 Thus, memory has an important role in addiction as it
stores the powerful incentives associated with drug taking that
produce a strong feeling of craving.5,22,24,26 Therefore, the
administration of cortisol could result in reduced retrieval of
addiction memory and, thereby, reduce feelings of craving.
To date, it is unknown whether exogenous glucocorticoids
would increase or rather decrease craving in heroin-dependent
patients. Because of the considerable clinical implications with
regard to understanding stress effects and regarding treatment of
addiction, the present study examined the effects of a single
administration of cortisol on craving in heroin-dependent patients.
We also examined whether cortisol effects depend on the daily
dose of heroin consumption as glucocorticoids have been shown
to interact with the opioid system.27
MATERIALS AND METHODS
Participants
All the participants were recruited from a standardized heroin-assisted
treatment protocol conducted at the treatment center JANUS, Psychiatric
University Clinics Basel, Basel, Switzerland. The heroin-assisted treatment
consists of the prescription of pharmaceutical heroin (diacetylmorphine)
twice a day combined with additional medical and psychosocial services.28
Additional services include medical care for somatic and psychiatric
conditions, weekly individual and group support sessions and help from
social workers.
Thirty-one participants with opioid dependence according to ICD-10
gave written informed consent to take part in the study. Sample size was
estimated on the basis of the assumption of a medium effect size at an
alpha level of 0.05 and a power of 0.8. Two participants had to be excluded
after study enrollment, one participant because of an additional psychiatric
axis I disorder identiﬁed during the medical examination for study
participation and the other participant because of illicit co-consumption of
a not-prescribed tranquilizer (ﬂunitrazepam) during the ﬁrst study day. The
remaining 29 participants (7 females, 22 males) completed the study and
were entered in the analyses (see Supplementary Information for ﬂow
diagram Supplementary Figure S1). Mean age was 42.4 (s.d. 7.9) years with
a mean duration of heroin consumption of 23.3 (s.d. 9.0) years and a
current daily intake of 395.8 (s.d. 171.1) mg heroin. Two out of seven
females took oral contraceptives (for additional demographic and
psychometric information, see Table 1).
Inclusion criteria consisted of an age older than 18 years, meeting
criteria for opioid dependence according to ICD-10 and having a past
history of intravenous heroin consumption with an unchanged heroin
intravenous substitution for at least 3 months. In addition, participants had
to be able to control parallel consumption of street drugs and were told to
abstain from illicit drug consumption for the duration of study participa-
tion. Blood alcohol level had to be below 30ml on both the study days. A
urine drug test (6-Panel Drug Test for screening for amphetamine,
benzodiazepine, cocaine/benzoylecgonine, methadone, opiates/morphine,
cannabis; Stephany Diagnostika, Grenzach-Wyhlen, Germany) and a
breathalyzer test (Dräger Alcotest 6510 Fuel Cell Breathalyzer, Lübeck,
Germany) were performed at the beginning of both the study days. Drug
screen results were considered as additional covariates in the statistical
model (see Results).
Exclusion criteria were a recent history of systemic or topical
glucocorticoid therapy or hypersensitivity to glucocorticoids, an axis I
disorder besides opioid dependence, current medical condition (such as
infectious disease), inability to read and understand the study consent
form, pregnancy or lactating. The local ethic committee and the Swiss
agency for the authorization and supervision of therapeutic products
(Swissmedic, Bern, Switzerland) approved the study. The study was
registered with ClinicalTrials.gov (http://clinicaltrials.gov/ct2/show/
NCT01718964?term=de+quervain&rank = 5). The blinding was maintained
throughout the study. All the participants received vouchers for local super-
markets (value 80 Swiss francs) as compensation for their participation.
Procedure and measurements
The study took place on two study days (120–135min duration each)
between 1230 and 1630 h at the JANUS center of the Psychiatric
University Clinics Basel, Basel, Switzerland in November 2012–July 2013.
Both study days were at least 1 week, but no longer than 3 weeks, apart.
Besides the initial screening at the beginning of the ﬁrst study day, both
Table 1. Demographic and baseline variable of interest characteristics
All (N= 29) Low-dose heroin group
(N=10)
Medium-dose heroin group
(N= 9)
High-dose heroin group
(N= 10)
P-values
Females/males 7/22 3/7 3/6 1/9 0.56
Oral contraceptives yes/no 2/5 1/2 0/3 1/0
Age 42.4 (7.9) 39.3 (8.6) 42.4 (7.5) 45.4 (7.1) 0.24
Heroin dosea 395.8 (171.1) 235.1 (70.2) 378.9 (35.3) 571.7 (147.1) o0.000001
Additional methadone yes/no 6/23 3/7 1/8 2/8 0.85
Dependency duration 23.3 (9.0) 19.6 (8.7) 24.8 (7.6) 25.7 (10.0) 0.27
Abstinence duration 5.95 (0.79) 6.07 (0.79) 6.20 (0.50) 5.59 (0.89) 0.16
Employed/unemployed 11/18 7/3 3/6 1/9 0.02
BMI 26.1 (4.4) 26.1 (5.9) 25.6 (3.5) 26.5 (3.7) 0.92
VASC 3.3 (2.4) 3.5 (2.4) 2.1 (2.0) 4.1 (2.4) 0.12
HCQ 12.9 (7.1) 12.7 (7.1) 11.3 (6.7) 14.7 (7.4) 0.54
STAI 36.5 (11.1) 37.4 (9.8) 33.2 (10.6) 38.5 (12.7) 0.54
STAXI 11.5 (3.0) 11.1 (2.1) 10.7 (1.7) 12.7 (4.2) 0.2
SOWS 11.4 (3.8) 10.9 (1.9) 10.0 (2.2) 13.3 (5.5) 0.1
Abbreviations: BMI, body mass index; HCQ, heroin craving index; SOWS, opiate withdrawal index; STAI, state anxiety index; STAXI, state anger expression
index; VASC, visual analog scale for craving. aCurrent daily heroin dose in mg= (daily intravenous heroin medication × 174.2)/200+(daily oral heroin
medication × 182)/200. Demographic variables are the number of males and females; age in years; heroin dose indicates the current daily heroin dose in mg;
additional methadone indicates the additional treatment with methadone; dependency duration indicates the duration of heroin dependency in years;
abstinence duration indicates the mean abstinence duration in hours between the last opiate administration in the morning and the beginning of the
baseline measures. Means of the baseline variable of interest values were calculated over the two testing days. Data presented as mean (s.d.). P indicates
P-values of heroin group effect on baseline variables of interest values.
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Figure 1. Course of the study. The x axis illustrates the time line. Study medication (that is, cortisol or placebo) is administered at 0 min.
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study days had the same procedure (see Figure 1). First, baseline saliva was
sampled and psychometric measures with the study test battery were
assessed. Afterwards, the study medication was administered followed by
a 1-h resting period allowing the absorption of the study medication. The
study test battery consisted of self-report measures, saliva samples and
examination of vital signs. This test battery was given a total of four times,
I–IV, on both study days (I: 15 min before administration of study
medication, II: 60 min after administration of study medication, III: 90 min
after administration of study medication, IV: 120min after administration
of study medication directly after heroin administration). Furthermore,
75min after the administration of study medication, a picture-rating task
was administered. The goal of this task was to investigate whether cortisol
affects craving ratings of drug- and nondrug-related pictures (see below).
Study medication. The participants were allocated randomly by time of
study entry to receive either oral cortisol (20 mg, two tablets each of 10mg
of hydrocortisone; Galepharm, Küsnacht, Switzerland) or placebo (two
similar looking tablets) at the ﬁrst study day. This dose of cortisol has been
used in previous studies investigating the effects of a single administration
of cortisol on phobic fear.29 After a washout period of 7–21 days,
participants received on the second study day the treatment (cortisol or
placebo) that they had not received on the ﬁrst study day. University
Hospital Pharmacy Basel prepared and blinded study medication (double-
blind, placebo-controlled crossover design).
Saliva measurements. Saliva was collected with Salivette (Sarstedt,
Rommelsdorf, Germany). Saliva samples were taken 15min before (−15)
and 60min after (+60) administration of study medication, directly after
stimuli presentation (+90) and after heroin intravenous (+120). Salivary
cortisol was analyzed as described before.29
Self-report measures of the test battery. The test battery was administered
at four time points on both the study days and included a primary
outcome measure (that is, craving) and secondary outcome measures (that
is, state anxiety, state anger and withdrawal symptoms). Craving: craving
was the primary outcome measure and assessed by visual analog scales for
craving (VASC). Visual analog scales have been successfully used to
measure the changes in emotional states.30 Participants had to indicate the
intensity of their craving on a continuous horizontal line (10 cm) with the
two end points—not at all (0) and very strong (10). Craving was also
measured with the ‘Desire to use heroin’ scale of the Heroin Craving
Questionnaire (HCQ). The scale originally consists of nine items scored
between 1 and 7 (total score ranges between 9 and 63, higher scores
indicate stronger craving).5 To avoid confusion, we excluded questions
that contained double negations, resulting in only ﬁve items (item 11, 17,
23, 39, 42) with a total score between 5 and 35. State anxiety: state anxiety
was measured with the German version of the State–Trait Anxiety
Inventory. The state scale of STAI consists of 20 items scored between 1
and 4 (total score ranges between 20 and 80, higher scores indicate higher
state anxiety). State anger: state anger was measured with the Anger
Expression Inventory (STAXI). The state scale of STAXI consists of 10 items
scored between 1 and 4 (total score ranges between 10 and 40, higher
scores indicate higher state anger). Withdrawal symptoms: withdrawal
symptoms were measured by nine selected items of the Short Opiate
Withdrawal Scale (SOWS) scored between 0 and 3 (total score ranges
between 0 and 27, higher scores indicate more and/or stronger
symptoms).
Picture-rating task. The goal of this task was to investigate whether
cortisol affects craving ratings of drug- and nondrug-related pictures.
Picture stimuli were presented in a darkened room on one laptop in
groups of maximal two participants at the same time. The picture stimuli
consisted of drug-related pictures and three categories of nondrug-related
pictures (that is, neutral, negative and positive photographs), with four
different pictures per category. Two comparable versions were used for the
two study days. The pictures were pseudo-randomized according to the
rule that pictures of the same category never followed one another.
Pictures were presented in the same order for all the participants. Each
picture was presented for 4 s and followed by a prompt to rate it for the
picture-characteristic craving by means of a visual analog scale. All the
pictures except the drug-related pictures were taken from the International
Affective Picture System. The drug-related pictures were nonstandardized
pictures showing themes related to drug use, like drug injection,
preparation of drugs and typical drug-consumption situations.
Statistical analysis
The ﬁve variables (VASC, HCQ, STAI, STAXI, SOWS) were measured at four
different time points: baseline (I), 60 min (II) and 90min (III) after study
medication intake and after heroin consumption (IV) as described above
(see also Figure 1). For each of the ﬁve variables of interest, we tested the
correlation structure for the four repeated measurements and observed a
decrease of correlation after heroin consumption. Therefore, we calculated
two separate models (1) for the two time points before heroin
consumption (II, III) and (2) after heroin consumption (IV). Analyses were
done in R (http://www.r-project.org/). We applied linear models and linear
mixed models (nlme-package) in combination with analysis of variance (SS
II), when necessary. In case of repeated measurements, participant was
included as the random effect of the mixed model. Dependent variables
were the measurements of the ﬁve variables of interest. Independent
variable was the study medication (placebo or cortisol).
To investigate whether cortisol effects depend on the daily heroin dose,
we divided the sample into three nearly equally sized heroin groups. This
group assignment allowed us to test not only for linear, but also for
nonlinear relationships between heroin consumption, study medication
and our variables of interest. Because the administered intravenous heroin
and the administered oral heroin medicament do not contain exactly the
same amount of active pharmaceutical ingredient, we quantiﬁed the
current daily heroin consumption according to the formula: daily heroin
consumption = (daily intravenous heroin medication× 174.2)/200+(daily
oral heroin medication× 182)/200. The three groups were as follows:
participants with low-dose (range 113–305mg, mean 235mg, N= 10),
medium-dose (range 330–451mg, mean 379mg, N= 9) and high-dose
(range 478–964mg, mean 572mg, N= 10) heroin consumption. This
allocation resulted in the maximal separation between the groups with
regard to the daily heroin consumption values. Group assignment was
entered as a factor in the model. We tested for main effects of study
medication and for interaction effects between heroin group and study
medication on our dependent variables. The baseline values (I) of the
variables of interest were included as covariate in all the models. We also
included treatment order as covariate in all the models. In case of repeated
measurement, the time point of measurement (60min or 90min) was
included as covariate. Due to the ﬁve variables of interest and two time
points tested, we set the signiﬁcance threshold to Po0.005 (Bonferroni
correction for 10 independent tests). In case of a Bonferroni-corrected
signiﬁcant interaction between heroin group and study medication, we
performed post hoc tests for each heroin group separately (nominal
signiﬁcance threshold Po0.05).
In addition, we analyzed craving ratings of drug-related and nondrug-
related pictures. This craving value was the dependent variable of the
linear model. Again, we tested for the independent main effect of
medication and the interaction between medication and heroin group.
Treatment order was included as a covariate.
RESULTS
Effects of study medication on salivary cortisol levels
There was a signiﬁcant main effect of study medication (cortisol/
placebo) on salivary cortisol levels, with signiﬁcant higher cortisol
levels under cortisol treatment at the three time points (that is, at
60min, 90 min and 120min) after medication (F(1,138) = 960.09,
Po0.00001; Supplementary Figure S2). In addition, we detected a
signiﬁcant main effect of the three heroin groups on cortisol levels
(F(2,25) = 3.69, P= 0.039). Post hoc t-tests showed signiﬁcantly
higher cortisol levels in the medium-dose heroin group compared
with the high-dose heroin group (F(1,16) = 8.00, P= 0.012), but no
signiﬁcant different cortisol levels between the low- and medium-
dose heroin groups (P= 0.37) or between the low- and high-dose
heroin groups (P= 0.12). However, we did not ﬁnd a signiﬁcant
interaction effect between heroin-dose group and study medica-
tion on cortisol levels (F(2,134) = 1.56, P= 0.21). Furthermore, there
were no differences between the heroin groups with regard to
cortisol levels at baseline or cortisol levels in the course of the
experiment in the placebo condition (P⩾ 0.12).
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Effects of study medication on primary and secondary outcome
measures
For the primary outcome craving, as quantiﬁed by VASC, there was
a signiﬁcant interaction (F(2,82) = 8.00, P= 0.00067) between
medication and heroin group (that is, low-, medium-, high-dose)
before heroin consumption, which survived Bonferroni correction.
We applied post hoc tests for the three heroin groups to test for an
inﬂuence of medication on VASC before heroin consumption (that
is, 60 min and 90min after the administration of study medica-
tion). Cortisol administration reduced VASC in the low-dose heroin
group (t(27) = 3.45, P= 0.0019; see Figure 2), but not for the
medium-dose (t(24) = 0.4, P= 0.70) or high-dose heroin group
(t(27) =− 1.42, P= 0.17). For the interaction between medication
and heroin group at the time point after heroin consumption,
there was only a trend (F(2,24) = 2.71, P= 0.087). For the sake of
completeness, we ran the post hoc tests also for the time point
after heroin consumption, which showed the same pattern,
meaning that cortisol administration reduced craving in the low-
dose heroin group (t(8) = 3.56, P= 0.0074, see Figure 2), but not in
the medium-dose (t(7) =− 0.63, P= 0.55) or high-dose heroin group
(t(7)− 0.66, P= 0.53).
In an additional analysis, we included all three time points at
once in the same linear mixed model (that is, 60 and 90min after
medication and after heroin consumption). Here again, we
identiﬁed a signiﬁcant interaction between medication and heroin
group on VASC (F(2,138) = 6.19, P= 0.0027).
We also tested for an exclusive linear relationship regarding the
interaction between medication and heroin consumption. There-
fore, we entered the amount of current daily heroin consumption,
instead of heroin group, in the model. We still observed a
signiﬁcant interaction between medication and heroin dose for
VASC (F(1,83) = 4.59, P= 0.035). To analyze whether the three
groups differed in the amount of drug co-consumption, we
calculated χ2 tests for each screened co-used drug. We found a
signiﬁcant association between heroin group and benzodiazepine
co-consumption (χ2(2) = 12.50, P= 0.0019), as well as a signiﬁcant
association between heroin group and methadone co-
consumption (χ2(2) = 10.29, P= 0.0058). No signiﬁcant association
was found between cocaine co-consumption and heroin group as
well as cannabis co-consumption and heroin group (both P40.46;
for a descriptive overview, refer to Supplementary Table S3).
Furthermore, the three groups did not differ in the amount of
smoked cigarettes during the resting period (F(2,26) = 0.78,
P= 0.47). In addition, we investigated whether the interaction
between the three heroin groups and medication on VASC might
have been owing to confounding variables, such as employment
status, duration of heroin dependency, benzodiazepine co-
consumption, cocaine co-consumption, cannabis co-consumption,
amount of smoked cigarettes during the resting period, additional
treatment with methadone, age or sex. The interaction between
heroin group and study medication was still observed when
entering these covariates separately in the model (medication ×
heroin group Po0.01 for all the analyses). The interaction
between heroin group and study medication on HCQ did reach
nominal signiﬁcance (P= 0.012), but did not survive Bonferroni
correction for multiple comparisons. There were no signiﬁcant
main effects of study medication on the ﬁve variables of interest
before and after heroin consumption (see Table 2). Furthermore,
for none of the secondary measures (STAI, STAXI, SOWS), we found
signiﬁcant main effects of study medication or study medication ×
heroin group interaction effects, which survived Bonferroni
correction (see Table 2).
Moreover, we analyzed whether the duration of opiate
abstinence interfered with cortisol-related effects on craving.
The mean abstinence duration between the last opiate adminis-
tration in the morning and the beginning of the baseline
measures was 5.95 h (s.d. = 0.79). There was no signiﬁcant main
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Figure 2. Effects of cortisol administration on craving. Means and
standard errors are displayed. Study medication was cortisol/
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effect of heroin group on abstinence duration (F(2,26) = 1.96,
P= 0.16) and no signiﬁcant interaction between medication and
heroin group on abstinence duration (F(2,84) = 0.90, P= 0.41).
Moreover, the signiﬁcant interaction between heroin group and
medication on VASC was still observed when entering the
covariate abstinence duration in the model (F(2,80) = 7.40,
P= 0.0011).
To rule out that limited cortisol uptake has masked potential
effects in the high-heroin group, we entered the salivary cortisol
levels, instead of the factor medication, in the model. We detected
a signiﬁcant interaction between cortisol levels and heroin groups
on VASC at the time point before heroin consumption
(F(2,82) = 8.94, P= 0.0003), which survived Bonferroni correction.
Post hoc tests for each heroin group separately revealed for the
low-dose group a signiﬁcant main effect of cortisol level on VASC
(t(27) =− 3.97, P= 0.0005), with cortisol reducing craving as
quantiﬁed by VASC, but no effect of cortisol level on VASC for
the medium-dose (t(23) = 0.13, P= 0.90) or high-dose heroin group
(t(23) = 1.05, P= 0.31) was detected. There was no Bonferroni-
corrected signiﬁcant interaction between cortisol level and HCQ
(F(2,81) = 4.30, P= 0.017), STAI (F(2,81) = 4.78, P= 0.01), STAXI
(F(2,81) = 4.16, P= 0.019) or SOWS (P= 0.38) at the time point
before heroin consumption, and no signiﬁcant main effect of
cortisol level on any of these variables (P40.60). For the time
point after heroin consumption, no Bonferroni-corrected signiﬁ-
cant interaction between cortisol and heroin group (all P40.27) or
main effects of cortisol (all P40.019) were detected.
We initially divided the sample into three heroin groups, which
allowed us to test not only for linear, but also for nonlinear
relationships between heroin consumption, study medication and
our variables of interest. We additionally divided our sample into
two equally sized groups, by means of a median split, to achieve
more power. The lower-dose heroin group (range 113–370 mg,
mean 268mg, N= 14) and the higher-dose group (range 382–
964mg, mean 515 mg, N= 15). There was a signiﬁcant interaction
between medication and heroin group (that is, lower dose and
higher dose) on VASC (F(1,83) = 24.37, P= 0.0000008), on HCQ
(F(1,83) = 14.38, P= 0.0003) and on STAI (F(1,82) = 13.43, P= 0.0004)
before heroin consumption, which survived Bonferroni correction.
No signiﬁcant Bonferroni-corrected interaction between medica-
tion and heroin group on SOWS or STAXI (all P40.03) or main
effects (all P40.70) were observed. We applied post hoc tests for
the two heroin groups separately to test for an inﬂuence of
medication on VASC, HCQ and STAI before heroin consumption
(that is, 60 min and 90min after the administration of study
medication). Cortisol administration signiﬁcantly reduced craving
as quantiﬁed by VASC (t(38) = 3.92, P= 0.0004) and by HCQ
(t(38) = 2.58, P= 0.01), and reduced state anxiety (t(38) = 2.39,
P= 0.02) in the lower-dose heroin group. There was a nominally
signiﬁcant main effect for enhanced VASC in the higher-dose
group (t(36) =− 2.48, P= 0.02), HCQ (t(36) =− 2.75, P= 0.009) and
STAI (t(36) =− 2.48, P= 0.01), indicating more craving and state
anxiety due to cortisol administration for the higher-dose group.
For the interaction between medication and heroin group on
VASC at the time point after heroin consumption, there was only a
trend (F(1,25) = 4.61, Puncorrected= 0.04) but not for HCQ, STAI, STAXI
or SOWS (all P40.21, main effects all P40.1).
Effects of study medication on the picture-rating task
In addition, we investigated the effects of the study medication on
ratings of drug- or nondrug-related pictures with regard to the
picture-characteristic craving. We did not ﬁnd signiﬁcant interac-
tions between medication, picture type and heroin-dose group,
between medication and picture type, or between medication and
the three heroin-dose groups on VASC (P⩾ 0.27). Furthermore,
there was no signiﬁcant main effect of medication on VASC
(F(1,85) = 0.08, P= 0.78), but a signiﬁcant main effect of picture type,
with higher craving ratings of drug-related pictures as compared
with nondrug-related pictures (F(1,85) = 62.71, Po0.001, see
Supplementary Tables S1 and S2).
Effects of study medication on adverse events
The rate of reported adverse events, which mainly consisted of
headache, tiredness or agitation, did not differ signiﬁcantly
between the cortisol and placebo condition (6 out of 30 patients
reported adverse events after placebo administration, while 8 out
of 29 patients reported adverse events after cortisol administra-
tion; Chi-square test: χ2 (1) = 1.04; P= 0.31).
DISCUSSION
The present study revealed that a single oral administration of
cortisol can signiﬁcantly reduce craving in heroin-maintained
patients. This craving-reducing effect of cortisol was heroin dose-
dependent and only found in patients receiving low-dose daily
heroin (that is, up to 305mg per day). State anxiety, state anger
and symptoms of opiate withdrawal were not signiﬁcantly
affected by cortisol.
Stress has been found to increase craving and the risk of relapse
to opioid dependence.18,19 Although animal studies have sug-
gested that glucocorticoids might be involved in mediating the
enhancing effects of stress on craving and relapse,18,31 studies in
humans failed to conﬁrm this postulated role of
glucocorticoids.32,33 The present ﬁnding of a cortisol-induced
reduction in craving suggests that glucocorticoids are not
Table 2. Cortisol effects on clinical symptoms
Variable P-values
Time point 60 and 90 min after study medication
(before heroin consumption)
Time point 120min after study medication
(after heroin consumption)
ME medication Medication× heroin group ME medication Medication× heroin group
VASC 0.32 0.00067* 0.8 0.087
HCQ 0.98 0.012 0.11 0.46
STAI 0.75 0.033 0.34 0.39
STAXI 0.67 0.025 0.095 0.62
SOWS 0.94 0.25 0.31 0.81
Abbreviations: HCQ, heroin craving index; ME, main effect; SOWS, opiate withdrawal index; STAI, state anxiety index; STAXI, state anger expression index;
VASC, visual analog scale for craving. *Po0.005, Bonferroni-corrected α level. For craving (VASC), there was a signiﬁcant interaction between study medication
and heroin group (low, medium, high dose) before heroin consumption, which survived Bonferroni correction for 10 comparisons (Po0.005).
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mediating the enhancing effect of stress on heroin craving, but
rather act as a stress buffer. A possible mechanism for the craving-
reducing effect of glucocorticoids may be their effects on memory
retrieval. Glucocorticoids have been shown to reduce retrieval of
previously acquired information in rodents and healthy
humans34,35 and there is evidence suggesting that emotionally
arousing information is particularly sensitive to these glucocorti-
coid effects.36 Furthermore, there is evidence that glucocorticoids
can also reduce the retrieval of aversive memory and enhance fear
extinction in posttraumatic stress disorder and phobia.29,30,37
There is growing evidence that memory and addiction partly
share neural circuitries and molecular mechanisms.22 It has been
proposed that critical neuroadaptations for addiction render
brain-reward systems hypersensitive to drugs and drug-associated
stimuli.26 Importantly, the powerful incentives associated with
drug taking that produce a strong feeling of craving5 are stored in
memory; also referred to as addiction memory.24 Moreover,
craving is triggered by contextual cues stored in memory.38
Therefore, in the present study, glucocorticoids may have reduced
craving by interfering with the retrieval of addiction memory and/
or contextual memory. According to this idea, cortisol should have
also reduced the rating of drug-related pictures with regard to the
picture-characteristic ‘craving’. However, we did not observe a
cortisol effect on the appraisal of drug-related cues when they are
explicitly presented. A possible explanation for the lack of cortisol
effect in this situation might be that explicitly shown drug-related
stimuli are too strong to be inﬂuenced by cortisol. Interestingly, a
similar discrepancy has been found with declarative memory,
where cortisol reduces memory retrieval in a free-recall task, but
not in a recognition task that involves the explicit presentation of
the stimuli.35
Alternatively, or in addition to the glucocorticoid effects on
memory, cortisol may have exerted direct effects on the reward
system, as previous studies have found that glucocorticoids can
effect dopaminergic transmission and reward behavior.39,40
However, the studies are not univocal with regard to the direction
of effect. For example, a study in rats has shown that acute
glucocorticoid administration acts in the nucleus accumbens to
enhance dopamine signaling and potentiate reinstatement of
cocaine seeking.39 In contrast, a study in healthy humans has
shown that acute glucocorticoid administration induces a global
downregulation of the brain’s reward circuitry.40
Interestingly, we found the craving-reducing effect of cortisol
only in patients with low-dose heroin consumption (113–305mg
per day). The three subgroups did not differ in age, gender
distribution or duration of dependency. Also the salivary cortisol
data at baseline or at the other time points of the experiment did
not explain why only the low-dose group responded to cortisol
administration. However, the medium- and high-dose heroin
consumption groups had more frequently an unemployment
status as compared with the low-dose consumption group,
indicating a more severe substance use disorder, which is
generally less responsive to regular treatment interventions.41,42
Alternatively, higher doses may have interfered directly or
indirectly with cortisol effects. For example, studies in rodents
have shown that glucocorticoids interact with the opioid system
to inﬂuence memory-retrieval mechanisms.27 Therefore, daily
consumption of higher heroin doses might have disturbed this
interaction through individual differences in sensitivity of the
opioid system or drug-induced downregulation of opioid recep-
tors. Furthermore, since nicotine is a strong modulator of the
hypothalamic–pituitary–adrenocortical axis,43 group differences in
the amount of daily cigarette smoking or in the smoking
abstinence duration before testing might have inﬂuenced cortisol
effects on craving. Unfortunately, these smoking data were not
available, which represents a limitation of the present study.
Finally, it is possible that higher doses of cortisol might have been
needed to reduce craving in patients receiving higher
heroin doses.
To conclude, we believe this is the ﬁrst study to examine the
acute effects of cortisol administration in a population of heroin-
dependent patients in a controlled study design. It shows that a
single administration of cortisol leads to reduced craving. Future
studies will need to identify potential factors that inﬂuence
cortisol effects on craving, such as sex-steroid hormones44 and to
explore the mechanism and the therapeutic potential of
glucocorticoids in drug addiction. In particular, it will be of
considerable clinical interest to investigate the effects of repeated
administration of glucocorticoids and whether glucocorticoids
might enhance exposure-based therapy, as it has been shown in
phobia.29 Moreover, it will be of interest to investigate whether
cortisol might be suited to prevent relapse in abstinent patients.
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